CD40/CD154 interactions at the interface of tolerance and immunity - PubMed
Review
CD40/CD154 interactions at the interface of tolerance and immunity
Sergio A Quezada et al. Annu Rev Immunol. 2004.
Abstract
Development of the acquired immune response is dependent on the signaling of CD40 by its ligand, CD154. These molecules govern both the magnitude and quality of humoral- and cell-mediated immunity. A litany of studies have conclusively documented that blockade of this ligand-receptor pair can prevent, and also intervene in, the progression of antibody- and cell-mediated autoimmune diseases, and can instill long-lived allogeneic and xenogeneic graft tolerance. Many effector mechanisms of inflammation are abolished as a result of CD154 blockade, but we are now beginning to understand that CD154 blockade may, in some instances, engender long-lived, antigen-specific tolerance. In the context of transplantation tolerance, we present a hypothesis that alpha CD154 blockade is most effective at inducing long-lived allospecific tolerance if anergy and regulation can be elicited prior to the onslaught of inflammation that is induced by grafting (preemptive tolerance). This facet of alpha CD154-induced tolerance appears to co-opt the normal processes of peripheral tolerance induced by immature DCs and can be exploited to induce long-lived antigen-specific tolerance. The underlying science and the prospects for inducing long-lived antigen-specific tolerance in a model of allograft tolerance through CD154 blockade are presented and discussed.
Similar articles
-
Karimi MH, Pourfathollah AA. Karimi MH, et al. Iran J Allergy Asthma Immunol. 2012 Mar;11(1):1-13. Iran J Allergy Asthma Immunol. 2012. PMID: 22427471 Review.
-
Gao W, Demirci G, Strom TB, Li XC. Gao W, et al. Transplantation. 2003 Sep 27;76(6):994-9. doi: 10.1097/01.TP.0000085010.39567.FB. Transplantation. 2003. PMID: 14508368
-
Determinations of B cell fate in immunity and autoimmunity.
Noelle RJ, Erickson LD. Noelle RJ, et al. Curr Dir Autoimmun. 2005;8:1-24. doi: 10.1159/000082084. Curr Dir Autoimmun. 2005. PMID: 15564715 Review.
-
Sun W, Wang Q, Zhang L, Liu Y, Zhang M, Wang C, Wang J, Cao X. Sun W, et al. Transplantation. 2003 Nov 15;76(9):1351-9. doi: 10.1097/01.TP.0000083557.25887.EE. Transplantation. 2003. PMID: 14627915
-
Disruption of CD154:CD40 blocks generation of allograft immunity without affecting APC activation.
Shepherd DM, Kerkvliet NI. Shepherd DM, et al. J Immunol. 1999 Sep 1;163(5):2470-7. J Immunol. 1999. PMID: 10452982
Cited by
-
Gaitonde P, Ramakrishnan R, Chin J, Kelleher RJ Jr, Bankert RB, Balu-Iyer SV. Gaitonde P, et al. J Biol Chem. 2013 Jun 14;288(24):17051-6. doi: 10.1074/jbc.C112.396325. Epub 2013 May 6. J Biol Chem. 2013. PMID: 23649621 Free PMC article.
-
Ford ML, Koehn BH, Wagener ME, Jiang W, Gangappa S, Pearson TC, Larsen CP. Ford ML, et al. J Exp Med. 2007 Feb 19;204(2):299-309. doi: 10.1084/jem.20062319. Epub 2007 Jan 29. J Exp Med. 2007. PMID: 17261633 Free PMC article.
-
Stone GW, Barzee S, Snarsky V, Kee K, Spina CA, Yu XF, Kornbluth RS. Stone GW, et al. J Virol. 2006 Feb;80(4):1762-72. doi: 10.1128/JVI.80.4.1762-1772.2006. J Virol. 2006. PMID: 16439533 Free PMC article.
-
Concepts for agonistic targeting of CD40 in immuno-oncology.
Richards DM, Sefrin JP, Gieffers C, Hill O, Merz C. Richards DM, et al. Hum Vaccin Immunother. 2020;16(2):377-387. doi: 10.1080/21645515.2019.1653744. Epub 2019 Sep 5. Hum Vaccin Immunother. 2020. PMID: 31403344 Free PMC article. Review.
-
Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response.
Obst R, van Santen HM, Mathis D, Benoist C. Obst R, et al. J Exp Med. 2005 May 16;201(10):1555-65. doi: 10.1084/jem.20042521. J Exp Med. 2005. PMID: 15897273 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials